Navigation Links
Virginia G. Piper Cancer Center vaccine study hopes to improve pancreatic cancer treatment
Date:6/13/2014

SCOTTSDALE, Ariz. June 12, 2014 Medical investigators at the Virginia G. Piper Cancer Center at Scottsdale Healthcare are studying a new cancer immunotherapy to see if it can successfully help patients with advanced pancreatic cancer.

The Phase 2B clinical trial of CRS-207 and GVAX Pancreas vaccines is open at Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare, a partnership with the Translational Genomics Research Institute (TGen), where cancer patients are treated with promising new drugs.

Participants in the study, named ECLIPSE (Efficacy of Combination Listeria/GVAX Immunotherapy in the Pancreatic Cancer Setting), will be randomized so patients receive only the CRS-207 vaccine, or that vaccine combined with the GVAX Pancreas vaccine and low doses of cyclophosphamide. A third group of patients will receive a standard chemotherapy.

"This is a very innovative approach using immunotherapy to treat pancreatic cancer," explained Dr. Erkut Borazanci, M.D., M.S., medical oncologist and Drug Development Scholar at Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare and the study's lead investigator.

The CRS-207 vaccine is a weakened form of the bacteria, Listeria monocytogenes, that has been genetically modified to be safe for human use, while retaining its ability to stimulate the immune system. Specifically, CRS-207 has been engineered to stimulate an immune response against the tumor-associated antigen mesothelin, which is present at high levels on pancreatic cancer cells.

The GVAX vaccine is composed of genetically modified, inactivated pancreatic cancer cells that have been shown to stimulate the immune system's anticancer activity. The vaccine is given with a low-dose of a common cancer drug called cyclophosphamide to boost the effectiveness of the vaccine.

In a recently completed Phase 2A trial in 93 patients with advanced pancreatic cancer, survival was improved in patients who received the combination regimen of CRS-207, GVAX and cyclophosphamide (6.1 months), compared to 3.9 months for those who received only cyclophosphamide and GVAX. The immunotherapies were well-tolerated, with no serious treatment-related adverse side effects.

Virginia G. Piper Cancer Center Clinical Trials is among the first 11 centers in the United States participating in the study. The drug was developed by Aduro BioTech, Inc., a clinical-stage immunotherapy company located in Berkeley, Calif. A total of 240 patients are expected to be treated at more than 20 clinical trial sites in North America.

"If this study is successful, we hope that this form of immunotherapy will become widely available across the country to treat patients with advanced pancreatic cancer," added Dr. Borazanci.

Pancreatic cancer is difficult to treat and is the fourth leading cause of cancer-related death in the U.S. Tumors may grow in the pancreas without any early symptoms, which means that the disease is often in an advanced stage when it is diagnosed, and survival remains poor.

Virginia G. Piper Cancer Center Clinical Trials is known worldwide for its expertise in studying new treatments for pancreatic cancer.

Individuals seeking information about eligibility to participate in clinical trials at the Virginia G. Piper Cancer Center at Scottsdale Healthcare may contact the cancer care coordinator at 480-323-1339; toll free at 1-877-273-3713 or via email at clinicaltrials@shc.org. Additional information is available at http://www.clinicaltrials.gov (NCT02004262).


'/>"/>
Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related medicine news :

1. Virginia Tech updates football helmet ratings, 5 new helmets meet 5-star mark
2. Virginia Tech scientists out for blood when it comes to stopping malaria
3. Class Action Lawsuit Filed on Behalf of West Virginia Residents Affected by Recent Chemical Spill
4. West Virginia Business Owners Represented in Class Action Lawsuit over Elk River Chemical Spill
5. The Bell Law Firm Filing Class Action Complaints on Behalf of West Virginia Contaminated Water Victims
6. Virginia Tech researchers find novice teen drivers easily fall into distraction, accidents
7. The Science Museum of Virginia Receives Largest Private Gift in Its History
8. Audiologists at Virginia Hearing Consultants in Norfolk VA Share Warnings about Everyday Ototoxic Drugs
9. Audiologists at Maico Audiological Services in Newport News Virginia Advise Consumers about Drugs that Lead to Hearing Loss
10. Northern Virginia Real Estate Company Pasquali Realty Group Suggests These New Year’s Resolutions For Homeowners
11. Northern Virginia Real Estate Company Pasquali Realty Group Announces Prices Up in November
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... The ... eligibility requirements effective with the April 2017 testing period. NACCM, a nonprofit organization, ... Care Manager Certified (CMC) exam is periodically re-calibrated to ensure that newly certified ...
(Date:2/22/2017)... ... February 22, 2017 , ... In a ... skipping doses or not filling a prescription because they could not afford to ... problems getting medications were 30-60%*. At the same time, hospitals, pharmacies, ...
(Date:2/22/2017)... ... February 22, 2017 , ... THR ... “NANOCALM 300” Microemulsified Hemp Extract. This premier nanoemulsified CBD product utilizes Quicksilver ... the bloodstream. Far outpacing the absorption speed of all other products, ...
(Date:2/22/2017)... ... February 22, 2017 , ... The ... Insights to help small practices in Delaware, New Jersey, Pennsylvania and West Virginia ... Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). , This technical ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... launched a new media platform connecting healthcare technology professionals and other key stakeholders ... by a quarterly publication starting on March 1, announced Michael J. Hennessy, Jr., ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... February 22, 2017 According to a new ... Trocar, SIMS, CUSCO), Application (Laparoscopy, Colposcopy, Hysteroscopy, D&C, Ablation, Biopsy), & ... 2021", published by MarketsandMarkets, the global market is expected to reach ... at a CAGR of 7.1% during the forecast period. ... ...
(Date:2/22/2017)... and PUNE, India , February 22, 2017 ... Market Research, titled, "Automated Radio Synthesis Modules Market: Global Opportunity ... radiosynthesis modules market was worth $20 million in 2015 and ... CAGR of 6.6% from 2016 to 2022. North ... of both market revenues and unit volumes, whereas ...
(Date:2/22/2017)... Feb. 22, 2017   Protein Sciences Corporation , ... Flublok® Influenza Vaccine , announced today that they donated ... Vaccine Introduction (PIVI) and the Mongolian Ministry of Health ... the flu.  The doses of Flublok have been distributed ... for health care workers, pregnant women, and ...
Breaking Medicine Technology: